From Diet To Vaccine: Doctor Discusses 6 Ways To Prevent Majority Of Cancers
While there's no guaranteed way to completely prevent cancer, experts say that certain lifestyle changes and habits can significantly reduce the risk.
"Patients who come for surgery tend to ask the most important question of life - How could I have avoided cancer?" Dr SK Bala, consultant- Surgical Oncology & Advanced Robotic Surgery, CMRI Kolkata, told NDTV.
Here Are Six Ways By Which The Majority Of Cancers Can Be Prevented
Don't Use Tobacco
Tobacco use is a major risk factor for numerous cancers, including lung, throat, mouth, bladder, and kidney cancer.
"Quitting smoking or avoiding tobacco products altogether is one of the most impactful steps you can take to reduce your cancer risk," Dr Bala said, adding that even being around secondhand smoke may raise the risk of lung cancer.
It's not only smoking that's harmful, chewing tobacco has been linked to cancer of the mouth, throat and pancreas.
Avoid Obesity and Exercise Regularly
Dr Bala said that being overweight or obese increases the risk of several cancers, including breast, colon and endometrial cancers.
Regular physical activity, even moderate-intensity exercise, can help you maintain a healthy weight and also directly reduce cancer risk.
"Aim for at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity exercise per week," he said.
Limit Alcohol Consumption
Excessive alcohol consumption is linked to an increased risk of several cancers, including liver, breast, colon and esophageal cancers.
"Limiting or avoiding alcohol intake can significantly lower your risk," Dr Bala said.
Eat Healthy Organic Foods
Eat a lot of fruit and vegetables. Focus on fruits, vegetables and other foods from plant sources, such as whole grains and beans. Limit foods high in calories, fats and added sugars. Limit red meat, processed meats, refined grains, and saturated and trans fats.
Get Vaccinated
Certain viral infections can increase cancer risk. "Vaccination against hepatitis B can prevent liver cancer, and the HPV vaccine can protect against cervical and other cancers," Dr Bala said.
Get Regular Medical Checkups and Screenings
Regular checkups and screenings can help detect cancer early, when it's often more treatable. Pap tests, mammograms, and other screenings are important for early detection and improved outcomes. Consult with your doctor about recommended screenings based on your age and risk factors.
Cancer Cases In India
Dr Bala said that not all cancers can be prevented because of "random genetic mutation or a strong family history". Furthermore, increasing air pollution, widespread pesticide use in agriculture, and unregulated chemicals in processed foods contribute to cancer risk, even for those without a family history or genetic predisposition.
The right way is to go for the recommended cancer screening. Moreover, never neglect any persistent symptoms (e.g. headache, pain in the abdomen, constipation, etc.) that have been present for more than a month. These common symptoms can be caused by cancer, and timely treatment can cure it completely.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
2 hours ago
- Indian Express
Doctor claims threading raises hepatitis risk: ‘Eyebrows banwane gayi thi lekin liver fail karwake aagayi'; internal medicine expert weighs in
In a video going viral on social media, MBBS Dr Aditij Dhamija can be seen saying that routine visits to neighbourhood parlours to get eyebrows shaped can expose one to 'liver failure risk' owing to hepatitis concern, as it happened in the case of a 28-year-old woman. 'Eyebrows banwane gayi thi lekin liver fail karwake aagayi. 28 saal ki mahila. (She went to get her eyebrows threaded, came back with liver failure). She came to the hospital with fatigue, nausea, and yellow eyes. Tests revealed her liver was giving up — not because of alcohol or medicines — but due to a beauty parlour visit gone wrong. This happened because reused threading material caused micro-cuts, through which Hepatitis B or C viruses entered her bloodstream,' said Dr Dhamija in an Instagram post. While it was unclear whether he treated the patient, his claim raises serious concerns about liver health. We reached out to an expert to understand the link between threading and liver health. Threading is a popular beauty treatment, most commonly for eyebrow shaping or facial hair removal. It is often considered quick, easy, and harmless. So, can it cause liver failure? Dr Amit Saraf, director, internal medicine, Jupiter Hospital, Thane, said threading itself does not cause liver failure, but can establish a risk for hepatitis B and C infections if not done under hygienic conditions. 'Hepatitis B and C are blood-borne viruses that are transferred via infected blood. If you get a small cut or abrasion from the threading, this could act as an entry point for infected blood. The thread, hands, or implements that are used could all pass on the virus, since we do not know if the hands or the thread are contaminated,' said Dr Saraf. Over time, once you have an untreated hepatitis infection, it could progressively damage the liver severely, and in some instances, lead to cirrhosis or liver failure. 'In summary, threading in itself is not dangerous to the liver, but can be risky depending upon the practices that are hygienic,' said Dr Saraf. A post shared by Dr. Aditij Dhamija | Health Educator | MBBS (@drdhamija) What should you note? Always ensure threading takes place in a clean, professional setting. 'Employing a new, disposable thread, washing hands, and sterilising the area before and after the process are simple but fundamental measures. It's also wise to refrain from threading in case of any cuts or active skin infection within the area,' said Dr Saraf. Individuals who get regular threading treatments done must be careful of the possible risks and must go to trained therapists who maintain very proper hygienic standards. DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.
&w=3840&q=100)
Business Standard
6 hours ago
- Business Standard
Hepatitis D virus labelled cancer-causing agent: All you need to know
The World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) has formally reclassified the Hepatitis D virus (HDV) as carcinogenic to humans, placing it alongside Hepatitis B and C as known causes of liver cancer. This reclassification, supported by data from a study published in The Lancet Oncology, marks a critical step in global efforts to raise awareness, improve screening, and expand access to new treatments for hepatitis D. What's the latest According to WHO, Hepatitis B, C, and D together affect over 300 million people globally, contributing to around 1.3 million deaths each year, primarily from liver cirrhosis and cancer. Current estimates suggest HDV infects nearly 5 per cent of people with chronic HBV (hepatitis B virus), equating to around 12 million individuals worldwide. High-risk populations include those in regions with elevated HBV prevalence, such as parts of Asia, Africa and the Amazon Basin as well as people who inject drugs and recipients of haemodialysis. Why is hepatitis D considered dangerous? HDV can only infect individuals who already carry HBV. HDV essentially hijacks HBV to replicate and cannot cause infection on its own. Co-infection or superinfection with HBV dramatically worsens outcomes as HDV raises the risk of liver cancer by two to six times compared with HBV alone, said the study. Up to 75 per cent of chronic HDV patients were likely to develop liver cirrhosis within 15 years, whereas individuals with only HBV were about 50 per cent less likely to develop liver cancer. The virus spreads through infected blood, unprotected sex, unsafe injections, or occasionally passes from mother to child during birth. Symptoms usually include fatigue, nausea, abdominal discomfort, dark urine or yellowing of the skin. Many people ignore these signs or confuse them with other illnesses. Treatment landscape While HBV can be controlled with life-long antivirals, options for HDV are more limited but evolving. The antiviral bulevirtide has emerged in Europe as an approved therapy offering improved outcomes alongside pegylated interferon in some cases. There is no separate vaccine for hepatitis D. The only way to stop it is by getting the hepatitis B vaccine, which protects against both viruses. According to WHO, as of 2025, 129 countries have adopted policies for hepatitis B testing among pregnant women, up from 106 reported in 2024. Meanwhile 147 countries have introduced the hepatitis B birth dose vaccination, an increase from 138 in 2022. However, the 2024 Global Hepatitis Report highlights major gaps in testing and treatment. By 2022, only 13 per cent of people with hepatitis B and 36 per cent with hepatitis C were diagnosed, while treatment rates were just 3 per cent and 20 per cent, respectively. This was well below the 2025 targets of 60 per cent diagnosed and 50 per cent treated. The integration of hepatitis services remains uneven, with only 80 countries incorporating hepatitis services into primary health care so far. What this means for public health The designation of HDV as Group 1 carcinogen by IARC is expected to mobilise funding, enhance surveillance and improve global awareness about its risks. Experts urge governments and health systems to scale up HBV vaccination coverage ensure universal testing in HBV-positive individuals expand access to novel HDV therapies To meet WHO's 2030 goals and potentially save 2.8 million lives while preventing 9.8 million new infections, countries must invest in domestic healthcare systems, ensure affordable medicines, improve data systems, and address stigmas. For more health updates, follow #HealthWithBS
&w=3840&q=100)
Business Standard
10 hours ago
- Business Standard
WHO, IARC officially label hepatitis D virus as cancer-causing agent
The World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) has formally reclassified the Hepatitis D virus (HDV) as carcinogenic to humans, placing it alongside Hepatitis B and C as known causes of liver cancer. This reclassification, supported by data from a study published in The Lancet Oncology, marks a critical step in global efforts to raise awareness, improve screening, and expand access to new treatments for hepatitis D. According to WHO, Hepatitis B, C, and D together affect over 300 million people globally, contributing to around 1.3 million deaths each year, primarily from liver cirrhosis and cancer. Current estimates suggest HDV infects nearly 5 per cent of people with chronic HBV (hepatitis B virus), equating to around 12 million individuals worldwide. High-risk populations include those in regions with elevated HBV prevalence, such as parts of Asia, Africa and the Amazon Basin as well as people who inject drugs and recipients of haemodialysis. Why is hepatitis D considered dangerous? HDV can only infect individuals who already carry HBV. HDV essentially hijacks HBV to replicate and cannot cause infection on its own. Co-infection or superinfection with HBV dramatically worsens outcomes as HDV raises the risk of liver cancer by two to six times compared with HBV alone, said the study. Up to 75 per cent of chronic HDV patients were likely to develop liver cirrhosis within 15 years, whereas individuals with only HBV were about 50 per cent less likely to develop liver cancer. The virus spreads through infected blood, unprotected sex, unsafe injections, or occasionally passes from mother to child during birth. Symptoms usually include fatigue, nausea, abdominal discomfort, dark urine or yellowing of the skin. Many people ignore these signs or confuse them with other illnesses. Treatment landscape While HBV can be controlled with life-long antivirals, options for HDV are more limited but evolving. The antiviral bulevirtide has emerged in Europe as an approved therapy offering improved outcomes alongside pegylated interferon in some cases. There is no separate vaccine for hepatitis D. The only way to stop it is by getting the hepatitis B vaccine, which protects against both viruses. According to WHO, as of 2025, 129 countries have adopted policies for hepatitis B testing among pregnant women, up from 106 reported in 2024. Meanwhile 147 countries have introduced the hepatitis B birth dose vaccination, an increase from 138 in 2022. However, the 2024 Global Hepatitis Report highlights major gaps in testing and treatment. By 2022, only 13 per cent of people with hepatitis B and 36 per cent with hepatitis C were diagnosed, while treatment rates were just 3 per cent and 20 per cent, respectively. This was well below the 2025 targets of 60 per cent diagnosed and 50 per cent treated. The integration of hepatitis services remains uneven, with only 80 countries incorporating hepatitis services into primary health care so far. What this means for public health The designation of HDV as Group 1 carcinogen by IARC is expected to mobilise funding, enhance surveillance and improve global awareness about its risks. Experts urge governments and health systems to scale up HBV vaccination coverage ensure universal testing in HBV-positive individuals expand access to novel HDV therapies To meet WHO's 2030 goals and potentially save 2.8 million lives while preventing 9.8 million new infections, countries must invest in domestic healthcare systems, ensure affordable medicines, improve data systems, and address stigmas. For more health updates, follow #HealthWithBS
